PTC Therapeutics (PTCT) Tops Q3 EPS by $1.32
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of $0.20, $1.32 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $211 million versus the consensus estimate of $174.39 million.
GUIDANCE:
PTC Therapeutics sees FY2025 revenue of $750-800 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Hudson Pacific Properties (HPP) Misses Q3 EPS by 265c
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
